California State Teachers Retirement System raised its holdings in shares of Audentes Therapeutics Inc (NASDAQ:BOLD) by 128.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,000 shares of the biotechnology company’s stock after acquiring an additional 15,200 shares during the quarter. California State Teachers Retirement System owned approximately 0.12% of Audentes Therapeutics worth $517,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the company. Nationwide Fund Advisors boosted its holdings in shares of Audentes Therapeutics by 288.9% in the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 6,384 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $210,000. Rhumbline Advisers acquired a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $252,000. Virtu KCG Holdings LLC acquired a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $257,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Audentes Therapeutics by 1,086.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,580 shares of the biotechnology company’s stock valued at $260,000 after buying an additional 12,435 shares during the last quarter. 78.99% of the stock is owned by institutional investors.
In other Audentes Therapeutics news, SVP David Nagler sold 3,750 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $25.00, for a total transaction of $93,750.00. Following the completion of the sale, the senior vice president now owns 3,750 shares of the company’s stock, valued at approximately $93,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew R. Patterson sold 10,000 shares of the firm’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $25.06, for a total value of $250,600.00. Following the sale, the chief executive officer now directly owns 1,542 shares of the company’s stock, valued at approximately $38,642.52. The disclosure for this sale can be found here. Insiders have sold a total of 761,500 shares of company stock valued at $21,457,100 in the last ninety days. Insiders own 47.30% of the company’s stock.
BOLD has been the subject of several recent analyst reports. Leerink Swann reissued an “outperform” rating and issued a $29.00 price objective (up previously from $22.00) on shares of Audentes Therapeutics in a report on Wednesday, November 15th. Zacks Investment Research downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Bank of America reissued a “buy” rating and issued a $33.00 price objective (up previously from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. Finally, BidaskClub downgraded Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Audentes Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $28.29.
Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) opened at $27.43 on Thursday. Audentes Therapeutics Inc has a twelve month low of $13.90 and a twelve month high of $33.43.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.88). equities analysts forecast that Audentes Therapeutics Inc will post -3.52 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “California State Teachers Retirement System Raises Stake in Audentes Therapeutics Inc (BOLD)” was reported by Stock Observer and is owned by of Stock Observer. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.thestockobserver.com/2017/12/07/california-state-teachers-retirement-system-raises-stake-in-audentes-therapeutics-inc-bold.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.